Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors.
This study is open to adults with different types of advanced cancer (solid tumours) that are accessible for injection. People for whom previous treatment was not successful or for whom no other treatment options exist can join the study.
Inclusions/Exclusions: Measurable disease. Tumors accessible to injection. ECOG 0-1. No prior VSV based agents.